MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

5-Fluorouracil

CAS No. : 51-21-8

MCE 國(guó)際站：5-Fluorouracil

產(chǎn)品活性：5-Fluorouracil (5-FU) 是一種尿嘧啶的類似物 (nucleoside antimetabolite/analog)，是一種有效的抗腫瘤藥。5-Fluorouracil 通過抑制胸苷酸合成酶影響嘧啶的合成，從而耗盡細(xì)胞內(nèi)dTTP 池。5-Fluorouracil 誘導(dǎo)細(xì)胞凋亡 (apoptosis)，可用作化學(xué)敏化劑。5-Fluorouracil 還可抑制 HIV 病毒。5-Fluorouracil (5-FU) 可破壞外泌體特異性的 rRNA。

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Anti-infection  |  Apoptosis  |  Metabolic Enzyme/Protease

作用靶點(diǎn)：Nucleoside Antimetabolite/Analog  |  HIV  |  Apoptosis  |  Endogenous Metabolite

In Vitro: 5-Fluorouracil (5-Fu) and NSC 123127 (Dox) show synergistic anticancer efficacy. The IC₅₀ value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells.

In Vivo: 5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Nucleotide Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Tumorigenesis-Related Compound Library  |  Children’s Drug Library  |  Chemotherapy Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Off-patent Drug Library  |  Mitochondrial Toxicity Compound Library  |  Cytokine Inhibitors Library  |  Cell Death Library  |  MG-132  |  Rapamycin  |  3-Methyladenine  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  ATP  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Retinoic acid  |  Elesclomol  |  Ruxolitinib  |  Decitabine

熱門產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds